Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

scientific article published on July 2014

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/INF.0000000000000240
P698PubMed publication ID24356256

P50authorXavier Sáez-LlorensQ68327803
P2093author name stringOctavio Ramilo
Genevieve A Losonsky
M Pamela Griffin
Rosanna Lagos
JoAnn Suzich
Kathryn M Jensen
C Kathy Wang
Brian S Harris
Motavizumab Study Group
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectviral loadQ2528140
hospitalizationQ3140971
P304page(s)703-709
P577publication date2014-07-01
P1433published inPediatric Infectious Disease JournalQ15756717
P1476titleMotavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness
P478volume33

Reverse relations

cites work (P2860)
Q59352372A Nonhospitable Host: Targeting Cellular Factors as an Antiviral Strategy for Respiratory Viruses
Q40823850A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease
Q40852832Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes
Q35893983An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice
Q92021897Antibody development for preventing the human respiratory syncytial virus pathology
Q36994087Antibody therapeutics for Ebola virus disease
Q30391416Antivirals for Respiratory Viral Infections: Problems and Prospects
Q30300567Challenges and opportunities in developing respiratory syncytial virus therapeutics
Q39038875Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons
Q38969434Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
Q47392075Discharge Criteria for Bronchiolitis: An Unmet Need
Q36438987Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Q36965855How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation
Q37729137Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design
Q38594067Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics
Q47886776Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses
Q38628928New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.
Q38604787Novel therapies and vaccines against the human respiratory syncytial virus.
Q30368680Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management
Q50262223Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
Q37651813Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.
Q92025172Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection
Q34542687Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein
Q38742141Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus
Q30657338Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth
Q35761061Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials
Q26796151Respiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention?
Q47548690Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
Q49997190Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
Q41921750The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, versus its achievable concentrations in the human respiratory tract and comparison to ribavirin.
Q28071857Viral Infection in the Development and Progression of Pediatric Acute Respiratory Distress Syndrome
Q52652828Virus-specific aNtibody, Viral Load and Disease Severity in Respiratory Syncytial Virus Infection.
Q91911845[Community-acquired pneumonia: Focus on viral CAP]

Search more.